A study of radiolabelled IPN60170 (Mesdopetam) elimination pathways in healthy adult male participants

The test treatment, IPN60170 (Mesdopetam), is in development for the treatment of levodopa -induced dyskinesia in Parkinson’s Disease. Parkinson’s Disease is a progressive nervous system condition that affects movement, caused by nerve cells in a specific area of the brain called the substantia nigra deteriorating or dying. Dyskinesia is uncontrolled or involuntary muscle movements that may occur with long-term levodopa use and a longer time with Parkinson’s. This study will be in healthy adult volunteers, so this trial is not to test if the drug helps to improve health. The test treatment, will be radiolabelled, meaning that it has a radioactive component. The radioactive component helps to track where the test medicine is in the body. This study will look at how much radioactivity can be recovered from the urine and faeces (mass balance recovery) and the rate and route of elimination of the test treatment. The use of a radiolabelled compound (usually carbon-14) is a common method used to collect information on the elimination routes and metabolic fate of a compound at an early stage of development.

En rapport Clinical Trials